Company intelligence / Profile preview

Screen Therapeutics

Rockville, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Screen Therapeutics is focused on preclinical programs utilizing proprietary ex vivo 3D platform technology to interrogate stromal-immune-tumor interactions and identify novel immuno-oncology drug targets; preliminary findings suggest targeting stromal and ECM proteins such as LAIR1 and CD163 for novel cancer immunotherapies[1][4][6].

Therapeutic areas: Oncology
Modalities: Biological productsPlatform technology (ex vivo 3D cultures)
Industry: Biotech

Partnerships

Immunaccel

Beyond the preview

Go deeper on Screen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Screen Therapeutics.

Explore the full profile